Chemistry: molecular biology and microbiology – Process of mutation – cell fusion – or genetic modification – Introduction of a polynucleotide molecule into or...
Reexamination Certificate
2007-07-31
2007-07-31
Guzo, David (Department: 1636)
Chemistry: molecular biology and microbiology
Process of mutation, cell fusion, or genetic modification
Introduction of a polynucleotide molecule into or...
C435S320100
Reexamination Certificate
active
10031639
ABSTRACT:
Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR are useful in the production of recombinant lentivirus vectors (See the Figure). Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production. The vectors can contain inducible or conditional promoters.
REFERENCES:
patent: 5503974 (1996-04-01), Gruber et al.
patent: 5583022 (1996-12-01), Heidmann et al.
patent: 5589362 (1996-12-01), Bujard et al.
patent: 5591579 (1997-01-01), Olivo et al.
patent: 5614404 (1997-03-01), Mazzara et al.
patent: 5650309 (1997-07-01), Wong-Staal et al.
patent: 5665577 (1997-09-01), Sodroski et al.
patent: 5681746 (1997-10-01), Bodner et al.
patent: 5693508 (1997-12-01), Chang
patent: 5716613 (1998-02-01), Guber et al.
patent: 5716826 (1998-02-01), Gruber et al.
patent: 5739118 (1998-04-01), Carrano et al.
patent: 5747307 (1998-05-01), Lever et al.
patent: 5994136 (1999-11-01), Naldini et al.
patent: 6365150 (2002-04-01), Leboulch et al.
patent: 2003/0104611 (2003-06-01), Johnston et al.
patent: 0 759 471 (1997-02-01), None
patent: WO 98/12314 (1998-03-01), None
patent: WO 99/04026 (1999-01-01), None
patent: WO 99/31251 (1999-06-01), None
Berkhout et al., “Tat Transactivates the Human Immunodeficiency Virus Through a Nascent RNA Target,” Cell, 1989, vol. 59: 273-282.
Blomer et al., “Highly Efficient and Sustained Gene Transfer in Adult Neurons with an Lentivirus Vector,” Jnl. of Virology, Sep. 1997, vol. 71(9): 6641-6649.
A. Bukovsky et al., “Interaction of Human Immunodeficiency Virus-Derived Vectors with Wild-Type Virus in Transduced Cells,” Jnl. of Virology, Aug. 1999, vol. 73(8): 7087-7092.
L-J Chang et al., “Efficacy and Safety Analyses of a Recombinant Human Immunodeficiency Virus Type 1 Derived Vector System,” Gene Therapy, 1999, vol. 6: 715-728.
JM Coffin, Fundamental Virology, 1996, 3rdEdition (Fields et al., eds), Chapter 26, “Retroviridae: The Viruses and Their Replication,” pp. 763-843, Lipincott-Raven Publishers, Philadelphia, PA.
T. Dull et al., “A Third Generation Lentivirus Vector with a Conditional Packaging System,” Jnl. of Virology, Nov. 1998, vol. 72(11): 8463-8471.
Elder et al., “Feline Immunodeficiency Virus as a Model for Development of Molecular Approaches to Intervention Strategies Against Lentivirus Infections,” Adv. Virus Res., vol. 45: pp. 225-247.
D. Farson et al., “Large-Scale Manufacturing of Safe and Efficient Rerovirus Packaging Lines for Use in Immunotheraphy Protocols,” Jnl. of Gene Medicine, 1999, vol. 1: 195-209.
N. Ferry et al., “Liver-Directed Gene Transfer Vectors,” Human Gene Therapy, Sep. 1998, vol. 9: 1975-1981.
M. Gasmi et al., “Requirements for Efficient Production and Transduction of Human Immunodeficiency Virus Type 1-Based Vectors,” Jnl. of Virology, Mar. 1999, vol. 73(3): 1828-1834.
T. Kafri et al., “Sustained Expression of Genes Delivered Directly Into Liver and Muscle by Lentiviral Vectors,” Nature Genetics, Nov. 1997, vol. 17: 314-317.
G. Kalpana, “Retroviral Vectors for Liver-Directed Gene Therapy,” Seminars in Liver Disease, 1999, vol. 19(1): 27-37.
Kim et al., “Construction of Retroviral Vectors with Improved Safety, Gene Expression, and Versatility,” Jnl. of Virology, Feb. 1998, vol. 72(2): 994-1004.
Lisziewicz et al., “Inhibition of Human Immunodeficiency Virus Type 1 Replication By Regulated Expression of a Polymeric Tat Activation Response RNA Decoy as a Strategy for Gene Therapy in AIDS,” Proc. Natl. Acad. Sci. USA, 1993, vol. 90: 8000-8004.
H. Miyoshi et al., “Development of a Self-Inactivating Lentivirus Vector,” Jnl. of Virology, Oct. 1998, vol. 72(10): 8150-8157.
L. Naldini et al., “Efficient Transfer, Integration, and Sustained Long-Term Expression of the Transgene in Adult Rat Brains Injected with a Lentiviral Vector,” Proc. Natl. Acad. Sci. USA, Oct. 1996, vol. 93: 11382-11388.
L. Naldini et al., “In Vivo Gene Delivery and Stable Transduction of Nondiving Cells by a Lentiviral Vector,” Science, Apr. 1996, vol. 272: 263-267.
D. Ory et al., “A Stable Human-Derived Packaging Cell Line for Production of High Titer Retrovirus/Vesicular Stomatitias Virus G Pseudotypes,” Proc. Natl. Acad. Sci. USA, Oct. 1996, vol. 93: 11400-11406.
R. Schneider et al., “Inactivation of the Human Immunodeficiency Virus Type I Inhibitory Elements Allows Rev-Independent Expression of Gag and Gag/Protease and Particle Formation,” Jnl. of Virology, Jul. 1997, vol. 71(7): 4892-4903.
R. Zufferey et al., “Multiply Attenuated Lentiviral Vector Achieves Efficient Gene Delivery In Vivo,” Nature Biotechnology, Sep. 1997, vol. 15: 871-875.
R. Zufferey et al., “Self-Inactivating Lentivirus Vector for Safe and Efficient In Vivo Gene Delivery,” Jnl. of Virology, Dec. 1998, vol. 72(12): 9873-9880.
Bukovsky Anatoly
Dull Thomas
Farson Deborah
Naldini Luigi
Witt Rochelle
Canady Karen S.
Canady & Lortz LLP
Cell Genesys Inc.
Guzo David
LandOfFree
Method and means for producing high titer, safe, recombinant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and means for producing high titer, safe, recombinant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and means for producing high titer, safe, recombinant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3789753